[A18-65] Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)
Last updated 02.01.2019
Commission awarded on 28.09.2018 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Adult patients with type 2 diabetes mellitus with inadequate glycaemic control by diet and exercise plus metformin monotherapy
Comparison with sulfonylurea (glibenclamide or glimepiride) + metformin: hint of non-quantifiable (at most considerable) added benefit. Comparison with glipizide + metformin: treatment goal near-normal blood glucose levels: hint of considerable added benefit; other treatment goal: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A16-44||Sitagliptin - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A13-02||Sitagliptin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|